CN102119170A - Mybl2表位肽及包含它的疫苗 - Google Patents

Mybl2表位肽及包含它的疫苗 Download PDF

Info

Publication number
CN102119170A
CN102119170A CN2009801308125A CN200980130812A CN102119170A CN 102119170 A CN102119170 A CN 102119170A CN 2009801308125 A CN2009801308125 A CN 2009801308125A CN 200980130812 A CN200980130812 A CN 200980130812A CN 102119170 A CN102119170 A CN 102119170A
Authority
CN
China
Prior art keywords
peptides
peptide
present
cancer
mybl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801308125A
Other languages
English (en)
Chinese (zh)
Inventor
角田卓也
大泽龙司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102119170A publication Critical patent/CN102119170A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2009801308125A 2008-06-10 2009-06-09 Mybl2表位肽及包含它的疫苗 Pending CN102119170A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6029308P 2008-06-10 2008-06-10
US61/060,293 2008-06-10
PCT/JP2009/002587 WO2009150822A1 (en) 2008-06-10 2009-06-09 Mybl2 epitope peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
CN102119170A true CN102119170A (zh) 2011-07-06

Family

ID=41416535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801308125A Pending CN102119170A (zh) 2008-06-10 2009-06-09 Mybl2表位肽及包含它的疫苗

Country Status (13)

Country Link
US (1) US20110189213A1 (https=)
EP (1) EP2297180A4 (https=)
JP (1) JP2011522777A (https=)
KR (1) KR20110016952A (https=)
CN (1) CN102119170A (https=)
AU (1) AU2009258775B2 (https=)
BR (1) BRPI0913436A2 (https=)
CA (1) CA2727482A1 (https=)
IL (1) IL209870A0 (https=)
MX (1) MX2010013688A (https=)
RU (1) RU2496787C2 (https=)
TW (1) TW201000119A (https=)
WO (1) WO2009150822A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104004062A (zh) * 2014-06-25 2014-08-27 苏州普罗达生物科技有限公司 关于per2蛋白激动剂多肽及其应用
CN104017054A (zh) * 2014-06-25 2014-09-03 苏州普罗达生物科技有限公司 Per2蛋白激动剂多肽及其应用
CN104045693A (zh) * 2014-06-25 2014-09-17 苏州普罗达生物科技有限公司 一种关于per2蛋白激动剂多肽及其应用
CN109073637A (zh) * 2016-05-13 2018-12-21 生物技术Rna制药有限公司 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法
CN109136376A (zh) * 2018-05-21 2019-01-04 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN109475579A (zh) * 2016-05-23 2019-03-15 昆士兰医学研究所理事会 Cmv表位
CN109963862A (zh) * 2016-09-07 2019-07-02 武汉华大吉诺因生物科技有限公司 多肽及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253486A (ja) * 1988-08-19 1990-02-22 Rikagaku Kenkyusho ヒトｍｙｂ関連遺伝子
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
TW200413406A (en) * 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
DE60327786D1 (de) * 2002-09-12 2009-07-09 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
CA2500982A1 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
EP2338994B1 (en) * 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CA2612449A1 (en) * 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
WO2007066423A1 (ja) * 2005-12-08 2007-06-14 Dainippon Sumitomo Pharma Co., Ltd. Ａｍａｃｒ由来の腫瘍抗原ペプチド
JP2009091249A (ja) * 2006-01-23 2009-04-30 Univ Kurume Ｃ型肝炎ウイルス２ａ由来ＨＬＡ−Ａ２拘束性抗原ペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SALA ET AL: "B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer", 《EUROPEAN JOURNAL OF CANCER》 *
SCHWAB R ET AL: "Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk", 《ONCOGENE》 *
SUDA TAKAKO ET AL: "Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy", 《CANCER SCIENCE》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104004062A (zh) * 2014-06-25 2014-08-27 苏州普罗达生物科技有限公司 关于per2蛋白激动剂多肽及其应用
CN104017054A (zh) * 2014-06-25 2014-09-03 苏州普罗达生物科技有限公司 Per2蛋白激动剂多肽及其应用
CN104045693A (zh) * 2014-06-25 2014-09-17 苏州普罗达生物科技有限公司 一种关于per2蛋白激动剂多肽及其应用
CN104017054B (zh) * 2014-06-25 2016-12-07 南安市威速电子科技有限公司 Per2蛋白激动剂多肽及其应用
CN109073637A (zh) * 2016-05-13 2018-12-21 生物技术Rna制药有限公司 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法
CN109475579A (zh) * 2016-05-23 2019-03-15 昆士兰医学研究所理事会 Cmv表位
CN109963862A (zh) * 2016-09-07 2019-07-02 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109963862B (zh) * 2016-09-07 2024-01-30 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109136376A (zh) * 2018-05-21 2019-01-04 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途

Also Published As

Publication number Publication date
KR20110016952A (ko) 2011-02-18
EP2297180A1 (en) 2011-03-23
RU2496787C2 (ru) 2013-10-27
RU2010154101A (ru) 2012-07-20
IL209870A0 (en) 2011-02-28
CA2727482A1 (en) 2009-12-17
AU2009258775B2 (en) 2013-10-10
JP2011522777A (ja) 2011-08-04
WO2009150822A1 (en) 2009-12-17
BRPI0913436A2 (pt) 2015-12-01
AU2009258775A1 (en) 2009-12-17
US20110189213A1 (en) 2011-08-04
TW201000119A (en) 2010-01-01
MX2010013688A (es) 2011-02-23
EP2297180A4 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
CN102119171B (zh) Cdca1表位肽及包含它的疫苗
US20110280898A1 (en) Inhbb epitope peptides and vaccines containing the same
US8367799B2 (en) TEM8 peptides and vaccines comprising the same
CN102186491B (zh) Hig2和urlc表位肽及包含它们的疫苗
US9193765B2 (en) Melk epitope peptides and vaccines containing the same
WO2009150835A1 (en) Iqgap3 epitope peptides and vaccines containing the same
AU2009258775B2 (en) MYBL2 epitope peptides and vaccines containing the same
AU2008238739B2 (en) TEM8 peptides and vaccines comprising the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20110706

C20 Patent right or utility model deemed to be abandoned or is abandoned